Private Capital Group’s Theravance Biopharma TBPH Stock Holding History

Private Capital Group’s Portfolio TBPH Stock Details TBPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-136	Closed	-$2K	–	2201
2021 Q4	$2K	Buy	+136	New	+$1.19K	﹤0.01%	1847

Other funds holding TBPH

Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Private Capital Group's TBPH Position: Q1 2022 in Review

Private Capital Group sold out of Theravance Biopharma (TBPH) in Q1 2022, closing a stake of 136 shares — an estimated $2K sold.

Private Capital Group first reported a position in TBPH in Q4 2021 and held it in 1 quarter. The position peaked at $2K in Q4 2021. 121 funds tracked by Wall St. Rank hold TBPH as of Q1 2022.

Private Capital Group reported no remaining Theravance Biopharma position as of Q1 2022 after selling out during the quarter.
Private Capital Group sold 136 Theravance Biopharma shares in Q1 2022, an estimated $2K.
Private Capital Group first reported a position in Theravance Biopharma in Q4 2021 and held it in 1 quarter.
Private Capital Group's Theravance Biopharma position peaked at $2K in Q4 2021.
121 funds tracked by Wall St. Rank held Theravance Biopharma as of Q1 2022.

Based on Private Capital Group's 13F filing for Q1 2022, filed 21 Apr 2022.